From: Evidence from a breast cancer hypofractionated schedule: late skin toxicity assessed by ultrasound
Age (years) | Median 62 (31–79) |
Menopausal status pre/post | 25/64 |
pT stage | |
pTis | 12 |
pT1 | 66 |
pT2 (≤3 cm) | 11 |
pN stage | |
pN0 | 70 |
pN1 (≤ 3 positive nodes) | 19 |
Estrogen receptor status | |
Positive/negative | 76/13 |
Progesteron receptor status | |
Positive/negative | 76/13 |
Chemotherapy yes/no | 36/53 |
Hormonotherapy | |
No | 20 |
Tamoxifen | 35 |
Anastrozole | 18 |
Letrozole | 16 |
Follow-up (months) | 20.5 (11.4-85.7) |